Treats mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin…. Sold as Coreg Cr. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 16, 2026, FDA lists 3 applications for Carvedilol Phosphate (sold as Coreg Cr), first approved Dec 19, 2008, with 0 new uses approved and 0 published complete response letters.
| Carvedilol ER | Part D | $28.2M | -12% | 19,626 |
| Coreg Cr | Part D | $4.9M | -44% | 331 |
| Dec 19, 2008 | Coreg CrNDA 22012 · TYPE 2/3 | Waylis Therap | 13 | Marketed |
| Oct 25, 2017 | Carvedilol PhosphateANDA 90132 | Sun Pharm Industries | 2 | Marketed |
| May 7, 2018 | Carvedilol PhosphateANDA 204717 | Impax Labs Inc | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA